Skip to main content

Table 2 Results of treatment

From: Clinical significance of tumor-infiltrating lymphocytes investigated using routine H&E slides in small cell lung cancer

  Total sTIL+ sTIL− p
Response to chemotherapy (case)     0.030
Treatment Sensitive (CR + PR) 123 65 58  
Treatment Resistant (SD + PD) 36 12 24  
Response to TRT (case)*     0.045
Treatment Sensitive (CR + PR) 63 38 26  
Treatment Resistant (SD + PD) 18 6 12  
mOS (moths) 16 18 12 0.030
1, 2, 3-year OS rate 59.8%, 28.6%, 19.8% 72.2%, 37.5%, 25.1% 48.0%, 19.9%, 5.1% 0.030
1, 2, 3-year PFS rate 31.5%, 13.1%, 6.2% 37.2%, 21.0%, 14.0% 25.9%, 4.2%, 4.2% 0.013
1, 2, 3-year BMFS rate** 75.0%, 47.2%, 47.2% 75.1%, 66.0%, 66.0% 75.5%, 11.4%, 11.4% 0.023
  1. *Patients administratived TRT and chemotherapy
  2. **Patients with non-BM and non-PCI